Terminal Signals

$DTE: Vantage Divestiture Funds $44B Utility Capex Surge • DTE sells ~$3B Vantage to J.P. Morgan AM infrastructure; closes 1H 2027. Proceeds cut equity and debt needs, funding $44B utility capex plan. • Long-term operating EPS growth target raised to >9% through 2031, up from prior 6%-8% CAGR; accelerated growth flagged for 2028-2029. • 7% dividend hike committed for 2027; $500M equity forward deferred from 2026 to 2027, signaling post-close capital structure reset.

$UI: Record Revenue; Component Cost Squeeze Emerging • Q1 FY2027 revenue hit record $1,026.2M (+39.9% YoY); GAAP diluted EPS surged 54.2% YoY to $5.29. • Gross margin expanded 130bps YoY to 47.3%, driven by lower indirect costs offsetting rising component prices. • Component costs rising since Q4 FY2026; supply constraints may cap revenue growth and compress margins if pricing offsets fail.

$VST: VST rose 6.19% premarket to $119.88 as of 7:05am ET after Q3 revenue beat consensus at $6.35B versus $5.94B, adjusted EBITDA grew 50% to $2.38B, and management initiated 2027 adjusted EBITDA guidance of $7.7B-$8.5B and FCFbG guidance of $4.3B-$5.1B. Strong Texas and East results outweighed a retail EBITDA miss (Bloomberg).

$CHTR: $108.6B Debt Load, $573M Cash • Free cash flow collapsed 58.4% YoY to $674M; $6.3B franchise impairment drove $2.4B actual net loss. • Pro forma Internet losses widened to 233K vs. 171K prior year; pro forma revenue declined 1.5% YoY. • Total debt at $108.6B against only $573M cash; credit facilities provide just $2.4B additional liquidity buffer.

$MRNA: MRNA is up 3.52% premarket to $249.95 as of 6:50am ET after Q3 revenue of $1.31B and EPS of $0.38 sharply beat Bloomberg consensus of $888.1M and a $1.09 loss, driven by stronger international COVID-vaccine sales and lower operating expenses. Moderna also raised 2026 revenue-growth guidance to 15%–25% from up to 10% and lifted year-end cash guidance to $8.1B–$8.3B, while Health Canada’s authorization of its flu and combined flu-COVID vaccines adds regulatory support.

$HUM: BlackRock JV Eliminates Put, Deleverages Balance Sheet • Q3 adjusted loss of $0.70/share beat ~$1.00 guidance; Insurance benefit ratio 93.7% beat 'slightly above 94%' target; FY2026 adjusted EPS floor raised $0.50 to at least $9.50. • Medical and pharmacy cost trends in line to better than high-single-digit expectations across both new and existing membership. • BlackRock JV carries no put option; eliminates multi-year put-funding obligation from former WCAS JVs, driving ~130 bps debt-to-cap reduction in Q4 with further deleveraging in 2027-2028.

$META: $15B Debt Raise and Class C Share Split Mechanic • Meta closed $15B in senior notes Nov 5, five tranches, coupons ranging 5.850%–7.500%, maturities 2031–2056. • Underwriters fully exercised 6M-share greenshoe Nov 4; total equity forward exposure now 46M shares at $622.91875/share. • Hidden alpha: Class C split mechanic in forward agreements automatically doubles Base Amounts and halves Forward Price on each Additional Class C Distribution per Founder Alignment Agreement with Zuckerberg.

$AXON: $1.2B Skydio Stake, Exclusive Distribution Rights • Axon acquires ~37% fully diluted Skydio stake at $5.2B pre-money valuation; $254.9M primary tranche closed November 5. • Axon becomes Skydio's exclusive U.S./Canada public safety distributor; Skydio targets ~$1B bookings in current fiscal year. • Axon stock issuance hard-capped at 19.99%; Tender Offer recipients face 45-day lock-up then 12-month daily volume selling restrictions.

$MNST: MNST closed down 1.89% at $47.83 at 4:00pm ET, then fell 6.54% to $44.70 as of 4:35pm ET after Q3 results exposed margin pressure: adjusted EPS merely matched at $0.30, gross margin missed at 54.7% versus 55.4% expected, operating margin was 28.0% versus 30.2%, and operating expenses exceeded estimates by roughly $53M. The selloff outweighed a revenue beat of $2.56B versus $2.49B, 18% volume growth and 28% international growth (Bloomberg).

$PNC: PNC closed down 2.87% at $226.75 at 4:00pm ET after reversing from a $239.56 intraday high. After the close, PNC announced CFO Robert Reilly will transition to Executive Vice Chairman and Retail Banking head Alexander Overstrom will become CFO on March 1, 2027; the quoted 1.57% after-hours decline to $223.20 as of 4:24pm ET predates that announcement and therefore cannot be attributed to the succession news.

$NET: NET reversed sharply after closing down 8.28% at $244.51 at 4:00 PM ET, rising 17.38% to $287.00 as of 4:21 PM ET after Cloudflare guided Q4 revenue to $845M-$846M versus $798.2M consensus and EPS to $0.43 versus $0.38. FY26 guidance was also above expectations at $2.963B-$2.964B revenue and $1.35 EPS versus $2.87B and $1.26 consensus.

$LRCX: LRCX closed down 16.36% at $185.20 at 4:00pm ET amid a broad semiconductor-equipment selloff driven by post-midterm concerns over tighter AI data-center regulation, slowing infrastructure spending, and Qualcomm’s weak guidance. Shares rebounded 3.13% to $191.00 by 4:20pm ET after Lam announced a new $25B share-repurchase authorization and maintained its $0.33 quarterly dividend.

$LYV: LYV closed down 1.05% at $181.25 at 4:00pm ET after reversing from a $187.88 intraday high, ahead of its post-close Q3 release. The new catalyst is a broad earnings beat—EPS of $1.69 versus $1.57 expected, revenue of $10.11B versus $9.59B, and adjusted operating income of $1.18B versus $1.16B—alongside 13% ticket-sales growth and guidance for nearly 180M fans in 2026; shares were unchanged after hours at $181.25 as of 4:06pm ET.

$MCHP: MCHP closed down 13.92% at $64.85 at 4:00pm ET as a broad semiconductor selloff intensified on post-midterm concerns that tighter AI-development policy could slow data-center investment. The stock extended its decline after hours, down 4.32% to $62.05 at 4:20pm ET, as Q2 beats were offset by softer Q3 guidance: adjusted EPS of $0.87-$0.95 versus Bloomberg consensus of $0.94 and revenue of $1.573B-$1.638B versus $1.62B, with the midpoint implying sequential contraction.

$DVN: Synergy Run-Rate Raised 75%; Solitude Pipeline LNG Exposure • Merger synergy run-rate raised 75% to ~$350M exit 2026; 2027 average synergies lifted to ~$700M, targeting $1B+ by year-end 2027. • Q4 buybacks step up to >$1B vs. $414M in Q3; Eagle Ford $3.5B net proceeds to fund further acceleration and $1.5B debt reduction. • Acquired 25% stake in Solitude Pipeline, securing firm Permian-to-Gulf Coast capacity with LNG-linked pricing — structural gas realization uplift catalyst.

$AXON: $130M Federal Slip, $225M Inventory Drag • Q3 gross margin compressed to 56.7% from 60.1% YoY; driven by counter-drone equipment mix, higher memory costs, and new product scaling. • Three Federal Dedrone deployments totaling ~$130M removed from 2026; full-year revenue growth guidance cut from 32–34% to ~30%. • Strategic inventory build consumes $225M cash in 2026; FCF suppressed below 60% EBITDA conversion target through at least Q1 2027.

$TEAM: Public Sector Pull-Forward, 44% RPO Surge • Q1 FY2027 revenue $1.772B (+24% YoY); RPO surged 44% to $4.746B, signaling durable forward demand. • GAAP operating margin flipped to +11% from -7% YoY; non-GAAP margin expanded 900bps to 32%. • Atlassian accelerated IL5 gov-cloud submission by 6 months to July 2028; FedRAMP High follows Jan 2029 — unlocks high-value regulated pipeline.

$LYFT: LYFT fell 8.80% after hours to $16.27 as of 4:16pm ET after reporting Q3 EPS of $0.03 versus $0.20 expected and revenue of $1.80B versus $1.91B expected; Bloomberg attributed the surprise loss partly to a legal settlement. The selloff followed a 4.80% regular-session decline to $17.84 at 4:00pm ET and came despite 17% gross-bookings growth and an in-line Q4 bookings and adjusted EBITDA outlook.

$TXRH: TXRH closed down 2.37% at $191.79 at 4:00pm ET, then fell 4.58% to $183.00 as of 4:04pm ET after Q3 results revealed late-quarter traffic softening and just 1.5% comparable-sales growth in the first five weeks of Q4. Despite 9.5% revenue growth, 8.6% EPS growth and 30 bps of restaurant-margin expansion, the company’s cautious initial 2027 outlook for merely positive comps alongside approximately 4% commodity inflation is pressuring sentiment.

$NTRA: NTRA closed down 6.97% at $363.76 at 4:00pm ET amid pre-earnings de-risking, then plunged 17.53% to $300.00 by 4:10pm ET following Q3 results. The sharp sell-the-news reaction came despite 34.1% revenue growth to $794.0M, 60.9% oncology-test growth and a $140M midpoint increase to 2026 revenue guidance, indicating elevated expectations outweighed the headline beat and positive Signatera immunotherapy data.